Immune Effector Cell Therapy Program News Today

(BPT) - For hematologist-oncologist Dr. Amitkumar Mehta, his passion is to help develop approaches to treat lymphoma, including immunotherapies and targeted therapies that are effective and tolerable. As a clinical

(BPT) - For hematologist-oncologist Dr. Amitkumar Mehta, his passion is to help develop approaches to treat lymphoma, including immunotherapies and targeted therapies that are effective and tolerable. As a clinical

(BPT) - For hematologist-oncologist Dr. Amitkumar Mehta, his passion is to help develop approaches to treat lymphoma, including immunotherapies and targeted therapies that are effective and tolerable. As a clinical

(BPT) - For hematologist-oncologist Dr. Amitkumar Mehta, his passion is to help develop approaches to treat lymphoma, including immunotherapies and targeted therapies that are effective and tolerable. As a clinical

(BPT) - For hematologist-oncologist Dr. Amitkumar Mehta, his passion is to help develop approaches to treat lymphoma, including immunotherapies and targeted therapies that are effective and tolerable. As a clinical trial investigator and director of the Lymphoma and Immune Effector Cell Therapy Program at the University of Alabama at Birmingham O’Neal Comprehensive Cancer Center, the only National Cancer Institute-designated comprehensive cancer center in the state, Dr. Mehta has been treating

Drs Lunning and Jacobson discuss the characteristics of follicular lymphoma that may prompt aggressive treatment, the potential optimal role of CAR T-cell therapy in the third line and beyond, and how the toxicity profiles of different CAR T-cell products compare with each other.

Patient preferences should be considered when selecting the optimal treatment regimen for patients with relapsed/refractory follicular lymphoma, as both CD19-directed CAR T-cell therapies and CD20-targeted bispecific antibodies can be efficacious in this population, according to a presentation by Caron A. Jacobson, MD, MMSc, at the 2023 SOHO Annual Meeting.

Key opinion leaders discuss barriers to care for using CAR T-cell therapy for patients with large B-cell lymphoma, including time delays and lack of support for patients.

Results include a landmark study that involved seamless collaboration across adult and pediatric patient groups, leading to a highly diverse study population. Other coverage addresses access to novel therapies and what's coming in the pipeline, including CAR T-cell therapy with tyrosine kinase inhibitors.

The autologous CAR T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated effectiveness and safety consistent with the ZUMA-5 trial when used in real-world settings to treat a broader population of patients with follicular lymphoma (FL).